Insights & Analysis
Curated perspectives on AI, real-world evidence, healthcare data science, and industry trends.
Every Wednesday: a concise take on real-world evidence, AI, or data science leadership. No fluff.
Featured Insights
Curated articles and analysis
The Rise of Foundation Models in Healthcare
How large-scale AI models are beginning to reshape clinical decision support, drug discovery, and evidence generation. From GPT-based clinical text analysis to multimodal models combining imaging and genomic data, foundation models promise to accelerate every stage of the evidence lifecycle.
Practical Applications of LLMs for Clinical Text
Exploring real-world use cases for large language models in extracting structured data from unstructured clinical notes, discharge summaries, and pathology reports. Key considerations include hallucination mitigation, validation frameworks, and regulatory implications for AI-generated clinical insights.
FDA's Evolving Stance on Real-World Evidence
A look at recent FDA guidance documents and how the regulatory environment for real-world evidence continues to mature for drug development and post-market surveillance. The 2025 framework updates signal growing acceptance of RWE for label expansion and safety monitoring decisions.
Best Practices for EHR-Based Studies
Key methodological considerations for designing rigorous observational studies using electronic health record data, from data quality assessment and phenotype validation to confounding control strategies and sensitivity analyses that strengthen causal claims.
2026 Trends in Healthcare Data Science
The top trends shaping healthcare analytics this year, from federated learning and synthetic data generation to the growing role of AI in health technology assessment. How organizations are building data science capabilities to meet evolving evidence demands.
Building High-Performance Analytics Teams
Lessons learned from scaling data science teams in healthcare organizations, including hiring strategies for blending clinical domain expertise with technical skills, structured mentorship programs, and building a culture of scientific rigor alongside business impact.
From the Wire
Latest news from across the healthcare data science landscape
STAT+: Alnylam to partner with Inceptive Nucleics for AI foundation models for RNAi therapeutics
Alnylam announced a three-year deal with Inceptive, worth up to $2 billion, with $30 million up front in cash and equity in the startup.
STAT+: HaloMD faces lawsuit alleging No Surprises Act middleman used ‘sham letter,’ misleading data
Highmark Health is the fourth insurer to sue HaloMD, seeking to overturn arbitration wins.
STAT+: What the pope’s encyclical on AI means for Catholic hospitals, and all of health care
In this edition of STAT's AI Prognosis: Brittany Trang analyzes the pope's encyclical on artificial intelligence for takeaways relevant for health care.
STAT+: Legend Biotech emerged as a rare market winner
New guidance for gene therapy developers, Lilly's deal for kidney drugs, and more biotech news from The Readout
STAT+: Pharmalittle: We’re reading about GLP-1 drugs and knees, FDA cell and gene therapy guidance, and more
Taking weight loss drugs for at least three years could prevent thousands of knee replacements a year, a new study found
FDA Issues Draft Guidance to Help Accelerate Cell and Gene Therapies for Patients
The U.S. Food and Drug Administration (FDA) today issued draft guidance to help developers bring promising gene therapies to patients more efficiently by making greater use of existing scientific and
FDA Issues Draft Guidance to Cut Unnecessary Animal Testing for Cancer Drugs
The U.S. Food and Drug Administration today issued a draft guidance to reduce unnecessary animal testing in nonclinical safety assessments for certain cancer drugs.
FDA Approves First Treatment for Chronic Hepatitis Delta Virus (HDV) Infection
Today, the U.S. Food and Drug Administration approved Hepcludex (bulevirtide-gmod) injection to treat chronic hepatitis delta virus (HDV) infection in adults without cirrhosis (advanced liver scarring
FDA Warns Retailers Selling Illegal Tobacco Products That Look Like Everyday Products
FDA Warns Retailers Selling Illegal Tobacco Products That Look Like Everyday Products
FDA Finalizes Food Chemical Safety Post-Market Assessment Program, Launches Reassessment of BHT, ADA
FDA continues to implement its bold food agenda, with two decisive actions focused on food chemical safety.
Health Affairs Web First: Choosing Wisely Campaign
In 2012, the American Board of Internal Medicine (ABIM) Foundation, in partnership with Consumer Reports, founded the Choosing Wisely® campaign, to raise awareness among physicians and patients about
The Transformation Of Medical Education From Choosing More To Choosing Wisely
Clinicians and patients value thoroughness. However, as new testing and treatment options have multiplied over the past few decades, the desire to leave no stone unturned has had unintended consequenc
Stay Connected
Follow along for the latest insights on AI, real-world evidence, and healthcare data science.